Anti-myeloma effects of the novel anthracycline derivative INNO-206

Clinical Cancer Research

Volumn 18, Issue 14, 2012, Pages 3856-3867

  Sanchez, Eric ^a   Li, Mingjie ^a   Wang, Cathy ^a   Nichols, Cydney M ^a   Li, Jennifer ^a   Chen, Haiming ^a   Berenson, James R ^a  

^a INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BORTEZOMIB; DOXORUBICIN; INNO 206; NEW DRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL ASSAY; CELL PROLIFERATION; CHORIOALLANTOIS; CONTROLLED STUDY; CYTOTOXICITY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; EXPERIMENTAL MOUSE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PH; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; DOXORUBICIN; HUMANS; HYDRAZONES; MICE; MULTIPLE MYELOMA; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; PYRAZINES;

EID: 84863979870     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-3130     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Berenson JR, Matous J, Swift RA, Mapes R, Morrison B, Yeh HS. A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma. Clin Cancer Res 2007;13:1762-8. (Pubitemid 46952943)
3. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;310:1353-6. (Pubitemid 14149087)
4. Weiss RB. The anthracyclines: will we ever find a better doxorubicin? Semin Oncol 1992;19:670-86. (Pubitemid 23004844)
5. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900-5. (Pubitemid 28446849)
6. Gianni L, Grasselli G, Cresta S, Locatelli A, Viganò L, Minotti G. Anthracyclines. Cancer Chemother Biol Response Modif 2003;21: 29-40.
7. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229. (Pubitemid 38720829)
8. Rifkin RM, Gregory SA, Mohrbacher A, Hussein MA. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a Phase III multicenter randomized trial. Cancer 2006;106:848-58. (Pubitemid 43238452)
9. Arcamone F, Animati F, Capranico G, Lombardi P, Pratesi G, Manzini S, et al. New developments in antitumor anthracyclines. Pharmacol Ther 1997;76:117-24. (Pubitemid 28078564)
10. Kratz F, Muller IA, Ryppa C, Warnecke A. Prodrug strategies in anticancer chemotherapy. Chem Med Chem 2008;3:20-53.
11. Orlowski RZ, Nagler A, Sonneveld P, Blade J, Hajek R, Spenser A, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma. J Clin Oncol 2007;25:3892-901. (Pubitemid 47477266)
12. Jakubowiak AJ, Kendall T, Al-Zoubi A, Khaled Y, Mineishi S, Ahmed A, et al. Phase II trial of combination therapy with bortezomib, pegylated liposomal doxorubicin, and dexamethasone in patients with newly diagnosed myeloma. J Clin Oncol 2009;27:5015-22.
13. Campbell RA, Manyak SJ, Yang HH, Sjak-Shie NN, Chen H, Popoviciv L. LAGlambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma. Int J Oncol 2006;28:1409-17.
14. Waterman GN, Yellin O, Swift RA, Mapes R, Eades B, AckermanE, et al. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone is effective and well tolerated in the treatment of relapsed or refractory multiple myeloma. Ann Hematol 2011;90: 193-200.
15. Berenson JR, Yellin O, Chen C-S, Patel R, Bessudo A, Boccia RV, et al. A modified regimen of pegylated liposomal doxorubicin, bortezomib, and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients. Br J Haematol 2011;155:580-7.
16. Popat R, Oakervee HE, Curry N, Foot N, Morris C, Drake M, et al. Reduced dose PAD combination therapy (PS-341/bortezomib, Adriamycin and dexamethasone) for previously untreated patients with multiple myeloma. Blood 2005;106:717a. Abstract nr 2554.
17. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. Drug Discov Today 2007;12:853-9. (Pubitemid 47554628)
18. Sachdev JC, Jahanzeb M. Evolution of bevacizumab-based therapy in the management of breast cancer. Clin Breast Cancer 2008;8:402-10
19. Zhang J, Sattler M, Tonon G, Grabher C, Lababidi S, Zimmerhackl A, et al. Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1a-dependent pathway in multiple myeloma. Cancer Res 2009;69: 5082-90.
20. Chen H, Wang CS, Li M, Sanchez E, Li J, Berenson A, et al. A novel angiogenesis model for screening anti-angiogenic compounds: the chorioallantoic membrane/feather bud assay. Int J Oncol 2010;37: 71-9.
21. Kratz F, Warnecke A, Scheuermann K, Stockmar C, Schwab J, Lazar P, et al. Probing the cystine-34 position of endogenous serum albumin with thiol-binding doxorubicin derivatives: improved efficacy of an acid-sensitive doxorubicin derivative with specific albumin-binding properties compared to that of the parent compound. J Med Chem 2002;45:5523-33. (Pubitemid 35424970)
22. Mundy GR, Raisz LG, Cooper RA, Schechter GP, Salmon SE. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 1974;291:1041-6.
23. Terpos E, Dimopulous MA. Myeloma bone disease: pathophysiology and management. Ann Oncol 2005;16:1223-31. (Pubitemid 41158467)
24. Berenson JR, Lichtenstein A, Porter L, Dimopoulos MA, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996;334:488-93. (Pubitemid 26067736)
25. Roodman DG. Biology of osteoclast activation in cancer. J Clin Oncol 2001;19:3562-71.
26. Blair HC, Teitelbaum SL, Ghiselli R, Gluck S. Osteoclast bone resorption by a polarized vacuolar proton pump. Science 1989;245:855-7. (Pubitemid 19223662)
27. Vaananen HK, Karhukorpi E-K, Sundquist K, Wallmark B, Roininen I, Hentunen T, et al. Evidence for the presence of a proton pump of the vacuolar H-ATPase type in the ruffled borders of osteoclasts. J Cell Biol 1990;11:1305-11.
28. Vaananen HK, Zhao H, Mulari M, Halleen JM. The cell biology of osteoclast function. J Cell Sci 2000;113:377-81. (Pubitemid 30116644)
29. Fallon MD. Alterations in the pH of osteoclast resorbing fluid reflects changes in bone degradative activity. Calcif Tissue Int 1984;36:458.
30. Nesbitt SA, Horton MA. Trafficking of matrix collagens through bone-resorbing osteoclasts. Science 1997;276:266-9. (Pubitemid 27172687)
31. Salo J, Lehenkari P, Mulari M, Metsikko K, Vaananen HK. Removal of osteoclast bone resorption products by transcytosis. Science 1997;276:270-3. (Pubitemid 27172688)
32. Hashim Al, Zhang X, Wojtkowaik JW, Martinez GV, Gillies RJ. Imaging pH and metastasis. NMR Biomed 2011;24:582-91.
33. Fais S. Proton pump inhibitor-induced tumor cell death by inhibition of a detoxification mechanism. J Intern Med 2010;267:515-25.
34. Gatenby RA, Gawlinski ET. A reaction-diffusion model of cancer invasion. Cancer Res 1996;56:5745-53. (Pubitemid 26422183)
35. Vukovic V, Tannock IF. Influence of low pHon cytotoxicity of paclitaxel, mitoxantrone and topotecan. Br J Cancer 1997;75:1167-72. (Pubitemid 27140029)
36. Graeser R, Esser N, Unger H, Fitchner I, Zhu A, Unger C, et al. INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model. Invest New Drugs 2010;28:14-9.
37. Kratz F, Ehling G, Kauffmann HM, Unger C. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl) hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin. Hum Exp Toxicol 2007;26:19-35.
38. Unger C, Haring B, Medinger M, Drevs J, Steinbild S, Kratz F, et al. Phase 1 and pharmacokinetic study of the (6-maleimidocaproyl) hydrazone derivative of doxorubicin. Clin Cancer Res 2007;13: 4858-66. (Pubitemid 47294793)
39. Campbell RA, Berenson JR. Animal models of multiple myeloma and their utility in drug discovery. In: Current protocols in pharmacology. Vol 40. Unite 14.9. Hoboken, NJ: John Wiley & Sons, Inc.; 2008. p. 14.9.1-14.9.22.
40. Babson AL, Winnick T. Protein transfer in tumor-bearing rats. Cancer Res 1954;14:606-11.
41. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986;46:6387-92. (Pubitemid 17221789)
42. Lebrecht D, Geist A, Ketelsen UP, Haberstroh J, Setzer B, Kratz F, et al. The 6-maleimidocaproyl hydrazone derivative of doxorubicin (DOXOEMCH) is superior to free doxorubicin with respect to cardiotoxicity and mitochondrial damage. Int J Cancer 2007;120:927-34. (Pubitemid 46175416)
43. Bertazzoli C, Rovero C, Ballerini L, Lux B, Balconi F, Antongiovanni V. Experimental systemic toxicology of 40-epidoxorubicin, a new, less cardiotoxic anthracycline antitumor agent. Toxicol Appl Pharmacol 1985;79:412-22. (Pubitemid 15059421)
44. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003;9:1136-44. (Pubitemid 36323723)
45. Bellamy WT, Odeleye A, Finley P, Huizenga B, Dalton WS, Weinstein RS, et al. An in vivo model of human multidrug-resistant multiple myeloma in SCID mice. Am J Pathol 1993;142:691-7.
46. Williams SS, Alosco TR, Mayhew E, Lasic DD, Martin FJ, Bankert RB. Arrest of human lung tumor xenograft growth in severe combined immunodeficient mice using doxorubicin encapsulated in sterically stabilized liposomes. Cancer Res 1993;53:3964-67. (Pubitemid 23267696)
47. Durie BG, Salmon SE. A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer 1975; 36:842-54.
48. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008;32:171-83.
49. Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, et al. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther 2010;9: 963-75.